TP53 and prostate cancer: For example, TP53I3 is regulated by the well-known cancer associated transcription factor TP53, and its response in our RNAi screen could indicate that the DNA damage pathway may be an effective therapeutic target in enzalutamide-resistant prostate cancer, for instance with PARP inhibitors.